Urokinase Plasminogen Activator Receptor-PET with Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand

Dorthe Skovgaard; Morten Persson; Andreas Kjaer

doi:10.1016/j.cpet.2017.02.003

Urokinase Plasminogen Activator Receptor-PET with Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand

Dorthe Skovgaard, Morten Persson, Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET

10 Citations (Scopus)

Abstract

Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

Original language	English
Journal	PET Clinics
Volume	12
Issue number	3
Pages (from-to)	311-319
Number of pages	9
ISSN	1556-8598
DOIs	https://doi.org/10.1016/j.cpet.2017.02.003
Publication status	Published - Jul 2017

Keywords

Gallium Radioisotopes
Humans
Ligands
Neoplasms/chemistry
Positron-Emission Tomography
Radionuclide Imaging/methods
Radiopharmaceuticals
Receptors, Urokinase Plasminogen Activator/analysis
Tomography, X-Ray Computed

Access to Document

10.1016/j.cpet.2017.02.003

Cite this

@article{2509bc56cca64d0bb342c4acad6f59b4,

title = "Urokinase Plasminogen Activator Receptor-PET with Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand",

abstract = "Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.",

keywords = "Gallium Radioisotopes, Humans, Ligands, Neoplasms/chemistry, Positron-Emission Tomography, Radionuclide Imaging/methods, Radiopharmaceuticals, Receptors, Urokinase Plasminogen Activator/analysis, Tomography, X-Ray Computed",

author = "Dorthe Skovgaard and Morten Persson and Andreas Kjaer",

year = "2017",

month = jul,

doi = "10.1016/j.cpet.2017.02.003",

language = "English",

volume = "12",

pages = "311--319",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B.Saunders Co",

number = "3",

}

TY - JOUR

T1 - Urokinase Plasminogen Activator Receptor-PET with Ga-NOTA-AE105

T2 - First Clinical Experience with a Novel PET Ligand

AU - Skovgaard, Dorthe

AU - Persson, Morten

AU - Kjaer, Andreas

PY - 2017/7

Y1 - 2017/7

N2 - Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

AB - Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

KW - Gallium Radioisotopes

KW - Humans

KW - Ligands

KW - Neoplasms/chemistry

KW - Positron-Emission Tomography

KW - Radionuclide Imaging/methods

KW - Radiopharmaceuticals

KW - Receptors, Urokinase Plasminogen Activator/analysis

KW - Tomography, X-Ray Computed

U2 - 10.1016/j.cpet.2017.02.003

DO - 10.1016/j.cpet.2017.02.003

M3 - Review

C2 - 28576169

SN - 1556-8598

VL - 12

SP - 311

EP - 319

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -

Urokinase Plasminogen Activator Receptor-PET with Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand

Abstract

Keywords

Access to Document

Fingerprint

Cite this